Literature DB >> 11102415

Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997).

J J Granizo1, L Aguilar, J Casal, R Dal-Ré, F Baquero.   

Abstract

The relationship between Streptococcus pyogenes resistance to erythromycin and macrolide consumption in Spain was studied. Erythromycin resistance was highly correlated with the consumption of total macrolides (r = 0.88, P<0.01). When macrolides were grouped into posological subgroups according to their pharmacokinetic and pharmacodynamic properties and analysed separately, erythromycin resistance appeared to be related mainly to those macrolides taken twice daily (bd) (r = 0.86, P<0.01) and those taken once daily (od) (r = 0.87, P<0.01), but not to those taken four (qds) or three times a day (tds) (r = -0.04, P: = 0.90). A progressive increase in the erythromycin resistance curve was seen after the consecutive introduction of both bd and od macrolides, which contributed to the increase in the total macrolide consumption, replacing tds macrolide prescription. Although this ecological analysis cannot establish an unequivocal causal relationship between antibiotic consumption and S. pyogenes resistance, the data are consistent with the hypothesis that widespread use of macrolides, mainly of bd and od macrolides, resulted in an increased prevalence of S. pyogenes resistant to erythromycin in Spain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102415     DOI: 10.1093/jac/46.6.959

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

1.  National Department of Defense surveillance data for antibiotic resistance and emm gene types of clinical group A streptococcal isolates from eight basic training military sites.

Authors:  Christopher P Barrozo; Kevin L Russell; Tyler C Smith; Anthony W Hawksworth; Margaret A K Ryan; Gregory C Gray
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

2.  Streptococcus pyogenes pharyngeal isolates with reduced susceptibility to ciprofloxacin in Spain: mechanisms of resistance and clonal diversity.

Authors:  Sebastián Albertí; Guadalupe Cortés; Cesar García-Rey; Carmen Rubio; Fernando Baquero; José Angel García-Rodríguez; Emilio Bouza; Lorenzo Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Utilisation of macrolides and the development of Streptococcus pyogenes resistance to erythromycin.

Authors:  Karel Urbánek; Milan Kolár; Luboslava Cekanová
Journal:  Pharm World Sci       Date:  2005-04

4.  Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains isolated from invasive and non-invasive infections from Mexico and the USA during 1999-2010.

Authors:  Alberto Villaseñor-Sierra; Eva Katahira; Abril N Jaramillo-Valdivia; María de los Angeles Barajas-García; Amy Bryant; Rayo Morfín-Otero; Francisco Márquez-Díaz; Juan Carlos Tinoco; José Sánchez-Corona; Dennis L Stevens
Journal:  Int J Infect Dis       Date:  2012-01-02       Impact factor: 3.623

5.  Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005.

Authors:  Emilio Pérez-Trallero; Milagrosa Montes; Beatriz Orden; Esther Tamayo; José M García-Arenzana; José M Marimón
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

Review 6.  The use of macrolides in treatment of upper respiratory tract infections.

Authors:  Aleksandra K Wierzbowski; Daryl J Hoban; Tamiko Hisanaga; Mel DeCorby; George G Zhanel
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

7.  The Use of Macrolides in Treatment of Upper Respiratory Tract Infections.

Authors:  Aleksandra K Wierzbowski; Daryl J Hoban; Tamiko Hisanaga; Mel Decorby; George G Zhanel
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004.

Authors:  Bogdan Luca-Harari; Kim Ekelund; Mark van der Linden; Margit Staum-Kaltoft; Anette M Hammerum; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2007-10-24       Impact factor: 5.948

10.  Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.

Authors:  C García-Rey; L Aguilar; F Baquero; J Casal; J E Martín
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.